

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Effect of treatment of hyperuricemia on lowering blood pressure in hemodialysis patients: single-blind, two-period randomized cross-over study

#### Protocol summary

##### Summary

We conducted a single-blind, two-period randomized cross-over clinical trial study to investigate the benefits of allopurinol treatment in hyperuricemic patients for reduction of high blood pressure (BP) in HD patients. A total of 53 patients enrolled in this study. Patients were randomly assigned into allopurinol (n:28) or control (n:27) groups. Patients in allopurinol group received 100 mg/day allopurinol for three months at the first phase of study. After that, patients passed two months washing period. Then, allopurinol was administrated for another three-month period followed by cross-over in second phase. The systolic and diastolic blood pressures were measured before and after dialysis at the first dialysis session of each week. Uric acid was also measured every month.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT138902043325N2**

Registration date: **2010-04-24, 1389/02/04**

Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2010-04-24, 1389/02/04

##### Registrant information

##### Name

Majgan Jalalzadeh

##### Name of organization / entity

Zanjan University Of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 24 1426 6934

##### Email address

jmojgan@zums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Zanjan University of Medical Sciences

##### Expected recruitment start date

2009-04-24, 1388/02/04

##### Expected recruitment end date

2009-06-26, 1388/04/05

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effect of treatment of hyperuricemia on lowering blood pressure in hemodialysis patients: single-blind, two-period randomized cross-over study

##### Public title

Effect of Allopurinol in lowering blood pressure in hemodialysis patients

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: having high level of serum uric acid (serum uric acid level greater than 6.5 mg/dl (men) or greater than 5.5 mg/dl (women). This definition was based on analyses from the Atherosclerosis Risk in Communities (ARIC) Study; Exclusion criteria: uric acid level of serum less than 6.5 for men and less than 5.5 for women, known history of allopurinol hypersensitivity or those who already were on allopurinol

**Age**

No age limit

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

No information

**Sample size**

Target sample size: 55

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Single blinded

**Blinding description****Placebo**

Not used

**Assignment**

Crossover

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Zanjan University of Medical Sciences

**Street address**

faculty of medicine, Zanjan University of Medical Sciences, shahrake karmandan, zanjan, iran

**City**

Zanjan

**Postal code****Approval date**

2010-05-30, 1389/03/09

**Ethics committee reference number**

19/3-3/976

**Health conditions studied****1****Description of health condition studied**

Hypertension

**ICD-10 code**

I12, I13,

**ICD-10 code description**

Hypertensive renal disease, Hypertensive heart and renal disease , Secondary hypertension

**2****Description of health condition studied**

Hyperuricemia

**ICD-10 code**

E79.0

**ICD-10 code description**

Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease Asymptomatic hyperuricaemia

**Primary outcomes****1****Description**

blood pressure

**Timepoint**

Baseline, at the beginning of each phase, each week for 3 month during each phase

**Method of measurement**

sphygmomanometer

**Secondary outcomes****1****Description**

blood level of uric acid

**Timepoint**

at the begining of study and after 3 months

**Method of measurement**

laboratory techniques

**Intervention groups****1****Description**

No intervention

**Category**

N/A

**2****Description**

Allopurinol a tablet (100 mg)/day,for 3 months

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Valieasr hemodialysis center

**Full name of responsible person**

Zeinolabedin Nourcheshmeh

**Street address****City**

Zanjan

**2****Recruitment center****Name of recruitment center**

Beheshti hemodialysis center

**Full name of responsible person**

Zeinolabedin Nourcheshmeh

**Street address****City**

Zanjan

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

samsami

**Street address**Zanjan University of Medical Sciences, Azadi  
boulevard, Zanjan, Iran**City**

Zanjan

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Zanjan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector***empty***Domestic or foreign origin***empty***Category of foreign source of funding***empty***Country of origin****Type of organization providing the funding***empty***Person responsible for general inquiries****Contact****Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Fateme Mirzamohammadi

**Position**

medical student

**Other areas of specialty/work****Street address**No:8, block: 5, Zeitoon Apartments, street 13,  
Shahrake Karmandan, Zanjan, Iran**City**

Zanjan

**Postal code****Phone**

+98 24 1426 6934

**Fax****Email**

fateme\_mm@yahoo.co.uk

**Web page address****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Fateme Mirzamohammadi

**Position**

medical student

**Other areas of specialty/work****Street address**No:8, block: 5, Zeitoon Apartments, street 13,  
Shahrake Karmandan, Zanjan, Iran**City**

zanjan

**Postal code****Phone**

+98 24 1426 6934

**Fax****Email**

fateme\_mm@yahoo.co.uk

**Web page address****Person responsible for updating data****Contact****Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Fateme Mirzamohammadi

**Position**

medical student

**Other areas of specialty/work****Street address**No:8, block: 5, Zeitoon Apartments, street 13,  
Shahrake Karmandan, Zanjan, Iran**City**

Zanjan

**Postal code****Phone****Fax****Email**

fateme\_mm@yahoo.co.uk

**Web page address****Sharing plan****Deidentified Individual Participant Data Set (IPD)***empty***Study Protocol***empty***Statistical Analysis Plan***empty***Informed Consent Form***empty***Clinical Study Report***empty***Analytic Code***empty***Data Dictionary***empty*